Krystal Biotech Q1 EPS Estimate Decreased by William Blair

Krystal Biotech, Inc. (NASDAQ:KRYS) – Analysts at William Blair reduced their Q1 2025 earnings estimates for shares of Krystal Biotech in a research report issued to clients and investors on Wednesday, April 2nd. William Blair analyst S. Corwin now anticipates that the company will post earnings of $1.31 per share for the quarter, down from their previous estimate of $1.47. The consensus estimate for Krystal Biotech’s current full-year earnings is $6.14 per share. William Blair also issued estimates for Krystal Biotech’s Q2 2025 earnings at $1.47 EPS, Q4 2025 earnings at $2.03 EPS, FY2025 earnings at $6.65 EPS, Q1 2026 earnings at $1.60 EPS, Q2 2026 earnings at $1.94 EPS and FY2026 earnings at $9.03 EPS.

Krystal Biotech (NASDAQ:KRYS) last issued its quarterly earnings data on Monday, February 24th. The company reported $1.52 EPS for the quarter, topping the consensus estimate of $1.29 by $0.23. The firm had revenue of $91.10 million for the quarter, compared to analyst estimates of $91.35 million. Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. The business’s revenue for the quarter was up 116.4% compared to the same quarter last year. During the same period in the prior year, the business posted $0.30 EPS.

KRYS has been the topic of several other research reports. Chardan Capital increased their target price on Krystal Biotech from $212.00 to $218.00 and gave the stock a “buy” rating in a research note on Thursday, February 20th. Cantor Fitzgerald reissued an “overweight” rating and issued a $215.00 price objective on shares of Krystal Biotech in a research note on Thursday, February 20th. HC Wainwright restated a “buy” rating and issued a $221.00 price objective on shares of Krystal Biotech in a report on Friday, February 28th. Jefferies Financial Group started coverage on shares of Krystal Biotech in a report on Wednesday, March 5th. They set a “buy” rating and a $245.00 target price on the stock. Finally, Citigroup boosted their price target on shares of Krystal Biotech from $206.00 to $215.00 and gave the stock a “neutral” rating in a research note on Thursday, February 20th. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, Krystal Biotech presently has an average rating of “Buy” and an average price target of $220.00.

Krystal Biotech Stock Down 4.4 %

KRYS opened at $158.69 on Monday. Krystal Biotech has a 52 week low of $141.72 and a 52 week high of $219.34. The business has a fifty day simple moving average of $173.44 and a 200-day simple moving average of $172.60. The firm has a market cap of $4.57 billion, a P/E ratio of 53.07 and a beta of 0.75.

Hedge Funds Weigh In On Krystal Biotech

Several institutional investors have recently added to or reduced their stakes in KRYS. Wilmington Savings Fund Society FSB purchased a new position in shares of Krystal Biotech in the 3rd quarter valued at approximately $40,000. GF Fund Management CO. LTD. acquired a new stake in shares of Krystal Biotech during the fourth quarter worth $95,000. Covestor Ltd grew its position in Krystal Biotech by 972.7% in the 4th quarter. Covestor Ltd now owns 708 shares of the company’s stock valued at $111,000 after buying an additional 642 shares during the last quarter. Avanza Fonder AB acquired a new position in Krystal Biotech in the 4th quarter valued at $119,000. Finally, KBC Group NV raised its position in Krystal Biotech by 46.3% during the 4th quarter. KBC Group NV now owns 939 shares of the company’s stock worth $147,000 after buying an additional 297 shares during the last quarter. Institutional investors and hedge funds own 86.29% of the company’s stock.

Insider Activity at Krystal Biotech

In other news, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $177.79, for a total transaction of $4,444,750.00. Following the sale, the insider now owns 1,463,711 shares in the company, valued at approximately $260,233,178.69. The trade was a 1.68 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CAO Kathryn Romano sold 750 shares of the business’s stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $175.22, for a total value of $131,415.00. Following the completion of the sale, the chief accounting officer now owns 12,604 shares of the company’s stock, valued at approximately $2,208,472.88. This represents a 5.62 % decrease in their position. The disclosure for this sale can be found here. 14.10% of the stock is currently owned by corporate insiders.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).